JCR Pharmaceuticals Co., Ltd. has made significant strides in gene therapy research, as highlighted at the 7th International Forum of Lysosomal Disorders.
During the forum, JCR Pharmaceuticals presented research focused on gene therapy approaches aimed at addressing LSDs. These disorders, often caused by enzyme deficiencies, lead to severe health issues, including organ dysfunction and neurological complications.
JCR’s research leverages their proprietary J-Brain Cargo® technology, designed to deliver therapeutic enzymes across the blood-brain barrier. This approach holds promise for treating central nervous system manifestations of LSDs, which are typically challenging to address with conventional therapies.
A key highlight of the presentation was JCR’s development of JR-171, a gene therapy candidate targeting mucopolysaccharidosis type I (MPS I). MPS I is a debilitating disorder characterized by the buildup of glycosaminoglycans in various tissues. Preliminary data from preclinical studies demonstrated JR-171’s potential to effectively deliver the therapeutic enzyme to both peripheral tissues and the brain.
Dr. Shin Ashida, President and Chairman of JCR Pharmaceuticals, emphasized the company’s commitment to pioneering gene therapies that address unmet medical needs. “Our goal is to develop transformative treatments that can significantly improve the quality of life for patients with lysosomal storage disorders,” said Dr. Ashida.